125I粒子条植入治疗原发性肝癌伴门静脉主干癌栓的近期疗效

目的探讨¹²⁵I粒子条植入治疗原发性肝癌伴门静脉主干癌栓的安全性及近期疗效。 方法15例原发性肝癌伴门静脉主干癌栓患者行门静脉¹²⁵I粒子条植入术，手术操作在超声及DSA引导下进行。术后对肝功能、血常规及凝血功能的变化、癌栓的改变、不良反应进行评价。 结果所有患者均成功植入放射性¹²⁵I粒子条，门静脉主干癌栓的有效率为40.00%(6/15)，疾病控制率为86.67%(13/15)。术后2个月复查所有患者的肝功能、血常规、凝血功能与术前比较差异无统计学意义。未出现与粒子条植入相关的严重并发症。 结论植入¹²⁵I粒子条治疗肝癌伴门静脉主干癌栓是安全、可行、有效的。

Evaluation the efficacy of 125I seed strand implantation for treatment of hepatocellular carcinoma with main portal vein tumor thrombus

ObjectiveTo discuss the therapeutic efficacy and safety of ¹²⁵I seed strand implantation for treatment of hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT). MethodsA total of 15 patients with confirmed HCC accompanied by MPVTT received implantation of ¹²⁵I seed strand via portal vein. The procedure was guided by ultrasound and DSA. The hepatic function, routine blood test as well as coagulation function, the changes of PVTT and the postoperative complications were analyzed. ResultsThe implantation of ¹²⁵I seed strand was successfully accomplished in all the patients. The objective response rate of MPVTT was 40.00% (6/15) and the disease control rate was 86.67% (13/15). There was no significant difference between preoperative and postoperative two months in hepatic function, routine blood test and coagulation function. No serious procedure-related complications occurred. ConclusionsImplantation of ¹²⁵I seed strand is safe, feasible and effective to treat MPVTT in HCC.